Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response
Our findings support the involvement of CD163 positive macrophages (M2c) in the pathophysiology of LN and advocate for the inclusion of usCD163/Cre measurement in the standard of LN management to assess LN flare episodes and as an early predictor of therapy response.
Authors
- G. Pugnet (ORCID: https://orcid.org/0000-0002-2621-204X)
- Stanislas Faguer (ORCID: https://orcid.org/0000-0003-0553-0927)
- Emmanuel Treiner (ORCID: https://orcid.org/0000-0001-6249-4534)
- L. Sailler (ORCID: https://orcid.org/0000-0003-3482-6903)
- Yves Renaudineau (ORCID: https://orcid.org/0000-0001-5098-5002)
- Julie Bellière (ORCID: https://orcid.org/0000-0002-4229-8584)
- Magali Colombat (ORCID: https://orcid.org/0000-0001-8317-2868)
- Antoine Huart (ORCID: https://orcid.org/0009-0002-3898-8731)
Institutions
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Toulouse Mathematics Institute (FR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-08-14
- DOI
- https://doi.org/10.1093/rheumatology/keaf446
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00